Antitope Ltd. (“Antitope”) today announced a research collaboration with the French Centre de Recherche du Service de Santé des Armées (“CRSSA”) in which Antitope will apply its proprietary EpiScreenTM technology to map T cell epitopes within CRSSA’s therapeutic antibody fragments.
“We are very pleased to be working with CRSSA and providing them with a preclinical assessment of immunogenicity,” said Dr Matthew Baker, Chief Scientific Officer and co-founder of Antitope. “We look forward to assisting CRSSA selecting lead antibody fragments with a low immunogenicity potential.” About Antitope Antitope Ltd. is a Cambridge UK-based biotechnology company specializing in immunogenicity testing and the engineering of therapeutic antibodies/proteins to reduce immunogenicity.
Antitope’s proprietary EpiScreenTM technology uses human T cells to measure the immunogenicity potential of biopharmaceuticals. Antitope’s Composite Human AntibodyTM and Composite ProteinTM technologies deliver novel therapeutic antibodies and proteins with very low immunogenicity potential through the avoidance of T cell epitopes. Antitope are a privately-held company and have established multiple commercial relationships with leading biotechnology and pharmaceutical companies. For further information on Antitope visit www.antitope.co.uk. For further information contact: Dr Neil Butt Business Development Director, Antitope Ltd. Tel: +44 (0)1223 496190
